- Expert in Infectious Diseases and Immune Oncology
- ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19
BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Professor Angus Dalgleish to its Scientific Advisory Board (SAB).
Angus Dalgleish, M.D. is the Foundation Chair of Oncology and Honorary Consultant in Medical Oncology at St. George’s University and Hospital in London and Principal of the Institute of Cancer Vaccines and Immunotherapy. He is a fellow of the Royal College of Physicians both in the UK and Australia, the Royal College of Pathologists, and the Academy of Medical Sciences (UK). Prof. Dalgleish published seminal papers on human immunodeficiency virus (HIV), its receptor on lymphocytes, and its pathogenesis.
“We are delighted to welcome Gus to our Scientific Advisory Board with his breadth of experience in developing antiviral drugs,” stated Jerome B. Zeldis, M.D., Ph.D., the acting Chief Medical Officer and Head of ViralClear Pharmaceuticals, Inc. “Gus’ expertise will complement those who are already on the SAB, and we look forward to working with him on this important mission.”
Professor Dalgleish said, “I am delighted to join the SAB of ViralClear Pharmaceuticals with my long-term collaborator, friend and colleague Jerry Zeldis with whom I worked with for several years successfully developing lenalidomide and pomalidomide, and I look forward to repeating this success against COVID-19.”
ViralClear recently announced the formation of its Scientific Advisory Board to review all aspects of drug discovery and development and advise the Company on its mission to control emerging infections and viral diseases of special interest, including COVID-19. Robin Robinson, Ph.D., the former Head of Biomedical Advanced Research and Development Authority (BARDA), J. Paul Waymack, M.D., ScD, formerly of the Food and Drug Administration and a pioneer antiviral drug developer Michael Sofia, Ph.D. were the first advisors appointed to the Board.
About BioSig Technologies
BioSig
Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
About Merimepodib and ViralClear
BioSig’s Technologies,
Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc.
(ViralClear), is seeking to develop a novel pharmaceutical called
merimepodib to treat patients with COVID-19. Merimepodib is intended to
be orally administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against SARS-CoV-2 in cell
cultures. Merimepodib was previously in development as a treatment for
chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated
(Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with
over 400 subjects and patients and an extensive preclinical safety
package was completed.
No comments:
Post a Comment